Vascular Grafts Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes, DelveInsight | BD, Getinge AB, Medtronic plc., B. Braun Melsungen AG, Cardinal Health, Terumo Corporation, W. L. Gore & Associates, Inc., JOTEC Gmb

The global vascular grafts market was valued at USD 1,863.09 million in 2024 and is projected to grow at a CAGR of 6.86% during the forecast period from 2025 to 2032, reaching USD 3,153.39 million by 2032. This growth is primarily fueled by the rising prevalence of cardiovascular diseases and contributing risk factors such as hypertension, obesity, and diabetes, which are increasing the need for surgical treatments. Moreover, greater awareness and the expansion of cardiovascular screening initiatives are enabling earlier diagnoses and timely medical interventions, further driving the demand for vascular grafts.

DelveInsight's Vascular Grafts Market Insights report provides the current and forecast market analysis, individual leading Vascular Grafts companies' market shares, challenges, Vascular Grafts market drivers, barriers, and trends, and key Vascular Grafts companies in the market.

Request for sample report: https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Vascular Grafts Market Report
The Vascular Grafts market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Vascular Grafts market during the forecast period.
Notable Vascular Grafts companies such as BD, Getinge AB, Medtronic plc., B. Braun Melsungen AG, Cardinal Health, Terumo Corporation, W. L. Gore & Associates, Inc., JOTEC GmbH, LeMaitre Vascular, Inc., Perouse Medical, CryoLife, Inc, BIOVIC Sdn Bhd, Abbott, Bentley, BioIntegral Surgical, Cook, Merit Medical Systems, SCITECH., Vascular Graft Solutions, Healionics, and several others are currently operating in the Vascular Grafts market.
In November 2024, Healionics was granted the FDA's Breakthrough Device designation for its StargraftTM arteriovenous graft, which is designed to enhance dialysis access outcomes by minimizing the risks of infection and thrombosis.
In January 2024, W. L. Gore & Associates announced that it had received FDA approval for the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE), marking the introduction of the first ready-to-use endovascular graft for treating complex aneurysmal conditions involving the visceral segment of the aorta.

To read more about the latest highlights related to the Vascular Grafts market, get a snapshot of the key highlights entailed in the Global Vascular Grafts Market Report: https://www.delveinsight.com/sample-request/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Vascular Grafts Overview

Vascular grafts are medical devices used to replace, bypass, or repair damaged or diseased blood vessels, particularly in cases where natural healing is insufficient. These grafts act as artificial conduits to restore or maintain proper blood flow in arteries or veins affected by conditions such as atherosclerosis, aneurysms, peripheral artery disease (PAD), or vascular trauma.

Vascular grafts can be classified based on origin (synthetic, biological, or composite) or application (coronary artery bypass, peripheral vascular procedures, or hemodialysis access). Synthetic grafts, often made from materials such as polytetrafluoroethylene (PTFE) or Dacron, are widely used due to their durability and compatibility with the human body. Biological grafts, including those derived from human or animal tissues, offer better biocompatibility and are less prone to infection or rejection.

The demand for vascular grafts is being driven by the rising prevalence of cardiovascular and chronic kidney diseases, increasing geriatric population, and growing number of vascular surgeries worldwide. Additionally, technological advancements, such as bioengineered and tissue-engineered grafts, along with favorable reimbursement policies and improved healthcare infrastructure, are supporting market expansion.

Vascular grafts play a crucial role in improving patient outcomes by ensuring effective blood circulation, especially in critical surgeries such as coronary artery bypass grafting (CABG), which is commonly performed in patients with severe coronary heart disease. As a result, the vascular grafts market continues to evolve with increasing investment in research, innovation, and clinical trials aimed at enhancing graft performance, longevity, and patient safety.

Vascular Grafts Market Insights

North America is projected to dominate the global vascular grafts market in 2024, holding the largest market share among all regions. This leadership is largely due to the region's high incidence of vascular diseases, advanced healthcare infrastructure, and the widespread adoption of modern surgical procedures such as endovascular repair. Additional contributing factors include the strong presence of key medical device manufacturers, increased healthcare expenditure, and supportive reimbursement frameworks. Moreover, heightened awareness surrounding early diagnosis and timely treatment of conditions like abdominal aortic aneurysms, coupled with a growing aging population, continues to bolster market growth in the region.

As per the Centers for Disease Control and Prevention (CDC, 2024), approximately 4.9% of U.S. adults were diagnosed with coronary heart disease in 2022. By 2023, an estimated 12.1 million Americans were living with atrial fibrillation. Furthermore, more than 795,000 strokes occur annually in the United States, with around 610,000 being first-time incidents. Notably, about 185,000 of these strokes happen in individuals with a prior history of stroke-highlighting the recurring nature and severity of vascular complications. These events, often resulting from blood clots that obstruct blood flow to the brain, frequently necessitate vascular graft procedures to restore proper circulation. With the continued rise in cardiovascular diseases driven by aging populations and risk factors like diabetes, hypertension, and obesity, the demand for both synthetic and biological vascular grafts is expected to steadily increase across North America.

To know more about why North America is leading the market growth in the Vascular Grafts market, get a snapshot of the Vascular Grafts Market Outlook https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Vascular Grafts Market Dynamics

According to the British Heart Foundation (2025), approximately 640 million individuals worldwide are living with heart and circulatory diseases. More specifically, coronary (ischemic) heart disease, the most prevalent form globally-affects an estimated 200 million people, including about 110 million men and 80 million women, as reported by the foundation in 2024.

Additionally, around 56 million women and 45 million men have survived strokes, and it is estimated that at least 13 million people are living with congenital heart disease, with many more potentially undiagnosed. These cardiovascular conditions frequently lead to damaged or obstructed blood vessels, necessitating surgical procedures to restore adequate blood flow. Vascular grafts-whether synthetic or biological-are commonly employed to repair, replace, or bypass these compromised vessels, contributing to increased demand in the vascular grafts market.

Moreover, the rising number of cardiovascular health awareness initiatives is significantly enhancing early detection, preventive care, and timely surgical interventions. Campaigns like World Heart Day, organized by the World Heart Federation, help raise global awareness about cardiovascular disease, its prevention, and the importance of early treatment. These initiatives encourage greater screening and the use of treatments such as vascular grafts, particularly for high-risk individuals, thereby driving further market growth.

Vascular Grafts Market Drivers:
Rising cases of cardiovascular disorders and associated risk factors
Increasing awareness and screening programs
Increase in product development activities

Get a sneak peek at the Vascular Grafts market dynamics @ https://www.delveinsight.com/sample-request/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Scope of the Vascular Grafts Market Report:
Coverage: Global
Study Period: 2022 to 2032
Key Vascular Grafts Companies: BD, Getinge AB, Medtronic plc., B. Braun Melsungen AG, Cardinal Health, Terumo Corporation, W. L. Gore & Associates, Inc., JOTEC GmbH, LeMaitre Vascular, Inc., Perouse Medical, CryoLife, Inc, BIOVIC Sdn Bhd, Abbott, Bentley, BioIntegral Surgical, Cook, Merit Medical Systems, SCITECH., Vascular Graft Solutions, Healionics, and others.

Which MedTech key players in the Vascular Grafts market are set to emerge as the trendsetter, explore @ Vascular Grafts Companies https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Table of Contents

1. Vascular Grafts Market Report Introduction
2. Vascular Grafts Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Vascular Grafts Market Key Factors Analysis
6. Vascular Grafts Market Porter's Five Forces Analysis
7. Vascular Grafts Market Layout
8. Vascular Grafts Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Info:

Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.